Growth and Management - Senior Clinical Document Specialist Ultragenyx Employee Review

2.0
Jan 21, 2020
Recommend
CEO approval
Business Outlook

Pros

I don't think Ultragenyx (UGNX) is a bad company. The CEO intentions are in the right place and he tries to keep his employees happy. The benefits and the flexible work schedules are above most companies.

Cons

I think it's time for the CEO to review his management staff. If you’re looking to grow in the Clinical Operations (CO) Department, then UGNX is not the company for you. UGNX CO department severely lacks qualified management, efficiency and quality. CO has a very high turnover and employee growth is not the priority. Management is hoping to grow with your experience, so your growth is not even on the table. Look into another company if you want to grow and advance in the Clinical Operations Department.

Explore other reviews about Ultragenyx

5.0
May 12, 2026
Recommend
CEO approval
Business Outlook

Pros

Great place with great people who are all pulling toward a common goal of bringing therapies to market that will change people's lives

Cons

For a small company, decisions can take a while to make because everyone wants to be involved, and most people in centralized roles work across all of the different brands within the company.

avatar
Ultragenyx Response
1mo
Thank you for your review and thoughtful feedback. We’re proud of the passion our teams bring to advancing therapies for patients, and we appreciate you sharing your perspective on how we work together. We’re glad to have you with us!
3.0
Jul 18, 2026
Recommend
CEO approval
Business Outlook

Pros

Good benefits and generally reasonable work-life balance.

Cons

In my experience, the organization had many layers of leadership (many VPs, Sr Directors and Directors), unclear decision-making authority, and frequently changing priorities, which sometimes slowed progress and weakened accountability. Considerable time was devoted to meetings, presentations, and strategy, but these activities did not always translate into measurable scientific outcomes. Hands-on scientists often appeared to have limited influence over technical decisions. Leadership also seemed to favor established hypotheses, outsourcing, and new biology-focused pilot studies over investing in innovative platform technologies that could address multiple diseases. Alternative perspectives and technical concerns did not always receive sufficient consideration. Career advancement appeared more accessible to highly visible employees with strong networking and presentation skills than to those contributing primarily through laboratory and technical work. While the benefits and work-life balance were positive, I would have valued clearer priorities, greater scientific openness, and stronger support for hands-on contributors.

See reviews by: Helpful|Rating|Date|All